thebench.bio

Industry Daily Summary

Industry Daily Summary: What Happened on October 5, 2026

Shionogi buys IntraBio for $2 billion

CSL will fund development of Alentis’ lixudebart, while Hansa Biopharma adopts Cradle’s protein-design platform.

  • Updated
  • Read from 3 articles, 3 publications
  • P M

Today in brief

Shionogi bought IntraBio for $2 billion.1 Alentis will receive $355 million upfront from CSL and could earn up to $1.2 billion in commercial milestones for lixudebart.2

Hansa Biopharma partnered with Cradle to use its protein-design platform across the discovery pipeline.3

CSL and Alentis partner on lixudebart

CSL and Alentis Therapeutics formed an exclusive global partnership to develop and commercialize lixudebart, an antibody that targets claudin-1.2 CSL will fund development, including ongoing and planned studies.2 Alentis will receive $355 million upfront and could earn up to $1.2 billion in additional commercial milestone payments.2 If lixudebart reaches the market, CSL would receive 55% of global profits and Alentis 45%.2

Alentis said an interim analysis of 26 patients in the Phase II RENAL study found improved kidney filtration and lower proteinuria, or protein in the urine, after 24 weeks.2 Alentis also reported improved liver function after six weeks in its Phase Ib FEGATO study of patients with advanced liver fibrosis.2 The companies plan Phase II studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis.2

Also published